Bioamber Inc (NYSE:BIOA) Director Kenneth W. Wall bought 40,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were bought at an average cost of $0.43 per share, for a total transaction of $17,200.00. Following the completion of the transaction, the director now directly owns 170,443 shares of the company’s stock, valued at $73,290.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Bioamber Inc (NYSE BIOA) traded down $0.03 during trading on Thursday, hitting $0.39. The stock had a trading volume of 1,167,987 shares, compared to its average volume of 946,754. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24. Bioamber Inc has a 12 month low of $0.32 and a 12 month high of $6.24.
BIOA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Bioamber in a research report on Wednesday, November 8th. Cowen reaffirmed a “hold” rating and set a $1.00 target price on shares of Bioamber in a research report on Friday, November 10th. Finally, ValuEngine lowered Bioamber from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $6.50.
Bioamber Company Profile
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
What are top analysts saying about Bioamber Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bioamber Inc and related companies.